Invasive fungal diseases in recipients of allogeneic hematopoietic stem cells: current state of the problem
https://doi.org/10.17650/1818-8346-2025-20-3-84-96
Abstract
Allogeneic hematopoietic stem cell transplantation is a standard treatment option for a variety of hematological disorders. In recent years, there has been observed an increase in transplantation activity worldwide as well as in use of alternative donors. Despite introduction of antifungal prophylaxis, recipients of allogeneic hematopoietic stem cells still have a high risk of invasive fungal disease.
This review represents risk factors, frequency and structure of invasive fungal disease in this category of patients.
About the Authors
D. A. Mironova
National Medical Research Center for Hematology, Ministry of Health of Russia
Russian Federation
Russian Federation
Daria Aleksandrovna Mironova
4 Novyy Zykovskiy Proezd, Moscow 125167
L. A. Kuzmina
National Medical Research Center for Hematology, Ministry of Health of Russia
Russian Federation
Russian Federation
4 Novyy Zykovskiy Proezd, Moscow 125167
G. A. Klyasova
National Medical Research Center for Hematology, Ministry of Health of Russia
Russian Federation
Russian Federation
4 Novyy Zykovskiy Proezd, Moscow 125167
References
1. Passweg J.R., Baldomero H., Chabannon C. et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant 2021;56(7):1651–64. DOI: 10.1038/s41409-021-01227-8
2. Mendeleeva L.P., Savchenko V.G., Parovichnikova E.N. et al. Analysis of transplantation activity in the Russian Federation for 2018 (report of the interregional register). Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2020;65(1-S1):180. (In Russ.).
3. Vasilyeva V.A., Kuzmina L.A., Parovichnikova E.N. et al. Implementation of allogeneic hematopoietic stem cell transplantation from unrelated donors from Russian and foreign registries. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2020;65(3):299–311. (In Russ.). DOI: 10.35754/0234-5730-2020-65-3-299-311
4. Rubinstein S.M., Culos K.A., Savani B., Satyanarayana G. Foiling fungal disease post hematopoietic cell transplant: review of prophylactic strategies. Bone Marrow Transplant 2018;53(2):123–8. DOI: 10.1038/bmt.2017.222
5. Tomblyn M., Chiller T., Einsele H. et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15(10):1143–238. DOI: 10.1016/j.bbmt.2009.06.019
6. Neofytos D., Horn D., Anaissie E. et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009;4(3):265–73. DOI: 10.1086/595846
7. Kontoyiennis D.P., Marr K.A., Park B.J. et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant- Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010;50(8):1091–100. DOI: 10.1086/651263
8. Girmenia C., Raiola A.M., Piciocchi A. et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant 2014;20(6):872–80. DOI: 10.1016/j.bbmt.2014.03.004
9. Martino R., Subirá M., Rovira M. et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002;116(2):475–82. DOI: 10.1046/j.1365-2141.2002.03259.x
10. Pagano L., Caira M., Nosari A. et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study – Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007;45(9):1161–70. DOI: 10.1086/522189
11. Nucci M., Garnica M., Gloria A.B. et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect 2013;19(8):745–51. DOI: 10.1111/1469-0691.12002
12. Kuster S., Stampf S., Gerber B. et al. Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: a Swiss transplant cohort study. Transpl Infect Dis 2018;20(6):e12981. DOI: 10.1111/tid.12981
13. Souza L., Nouér S.A., Morales H. et al. Epidemiology of invasive fungal disease in haematologic patients. Mycoses 2021;64(3):252–6. DOI: 10.1111/myc.13205
14. Gao L., Sun Y., Meng F. et al. Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study. J Hematol Oncol 2016;9(1):97. DOI: 10.1186/s13045-016-0305-y
15. Klyasova G.A., Okhmat V.A., Vasilieva V.A. et al. Invasive mycoses in patients with acute leukemia and in recipients of hematopoietic stem cells. Results of a multicenter prospective observational study in Russia (RIFI). Gematologiya i transfuziologiya = Hematology and Transfusiology 2016;61(1-S1):19. (In Russ.).
16. Cesaro S., Tridello G., Blijlevens N. et al. Incidence, risk factors, and long-term outcome of acute leukemia patients with early candidemia after allogeneic stem cell transplantation: a study by the acute leukemia and infectious diseases working parties of European Society for Blood and Marrow Transplantation. Clin Infect Dis 2018;67(4):564–72. DOI: 10.1093/cid/ciy150
17. Robin C., Cordonnier C., Sitbon K. et al. Mainly post-transplant factors are sssociated with invasive aspergillosis after allogeneic stem cell transplantation: a study from the Surveillance des Aspergilloses Invasives en France and Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Biol Blood Marrow Transplant 2019;25(2):354–61. DOI: 10.1016/j.bbmt.2018.09.028
18. Martino R., Parody R., Fukuda T. et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006;108(9):2928–36. DOI: 10.1182/blood-2006-03-008706
19. Popova M.O., Ekushov K.A., Ayzsilnieks O.V. et al. Invasive fungal infections in recipients of allogeneic hematopoietic stem cell teens and young adults. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2016;3(1):44–51. (In Russ.). DOI: 10.17650/2311-1267-2016-3-1-44-51
20. Busca A., Cinatti N., Gill J. et al. Management of invasive fungal infections in patients undergoing allogeneic hematopoietic stem cell transplantation: the Turin experience. Front Cell Infect Microbiol 2022;11:805514. DOI: 10.3389/fcimb.2021.805514
21. Papanicolaou G.A., Chen M., He N. et al. Incidence and impact of fungal infections in post-transplantation cyclophosphamidebased graft-versus-host disease prophylaxis and haploidentical hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant research analysis. Transplant Cell Ther 2023;30(1):114.e1–16. DOI: 10.1016/j.jtct.2023.09.017
22. Penack O., Tridello G., Salmenniemi U. et al. Influence of invasive aspergillosis during acute leukaemia treatment on survival after allogeneic stem cell transplantation: a prospective study of the EBMT Infectious Diseases Working Party. eClinicalMedicine 2023;67:102393. DOI: 10.1016/j.eclinm.2023
23. Cornely O.A., Hoenigl M., Lass-Flörl C. et al. Defining breakthrough invasive fungal infection – position paper of the Mycoses Study Group Education and Research Consortium (MSG-ERC) and the European Confederation of Medical Mycology (ECMM). Mycoses 2019;62(9):716–29. DOI: 10.1111/myc.12960
24. Van Burik J.H., Leisenring W., Myerson D. et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 1998;77(4):246–54. DOI: 10.1097/00005792-199807000-00003
25. Lamoth F., Chung S.J., Damonti L., Alexander B.D. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis. Clin Infect Dis 2017;64(11):1619–21. DOI: 10.1093/cid/cix130
26. Trifilio S., Singhal S., Williams S. et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007;40(5):451–6. DOI: 10.1038/sj.bmt.1705754
27. Bergamasco M.D., Pereira C.A.P., Arrais-Rodrigues C. et al. Epidemiology of invasive fungal diseases in patients with hematologic malignancies and hematopoietic cell transplantation recipients managed with an antifungal diagnostic driven approach. J Fungi 2021;7(8):588. DOI: 10.3390/jof7080588
28. Roth R.S., Masouridi-Levrat S., Chalandon Y. et al. Invasive mold infections in allogeneic hematopoietic cell transplant recipients in 2020: have we made enough progress? Open Forum Infect Dis 2021;9(1):ofab596. DOI: 10.1093/ofid/ofab596
29. Sun Y., Meng F., Han M. et al. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study. Biol Blood Marrow Transplant 2015;21(6):1117–26. DOI: 10.1016/j.bbmt.2015.03.018
30. Posteraro B., De Carolis E., Criscuolo M. et al. Candidaemia in haematological malignancy patients from a SEIFEM study: epidemiological patterns according to antifungal prophylaxis. Mycoses 2020;63(9):900–10. DOI: 10.1111/myc.13130
Review
For citations:
Mironova D.A., Kuzmina L.A., Klyasova G.A. Invasive fungal diseases in recipients of allogeneic hematopoietic stem cells: current state of the problem. Oncohematology. 2025;20(3):84-96. (In Russ.) https://doi.org/10.17650/1818-8346-2025-20-3-84-96
Views:
11
Email this article 